CAS: 239807-03-5; Voriconazole Impurity 8
物理性质
- 沸点320.3±37.0 °C at 760 mmHg
- 闪点147.5±26.5 °C
- 密度1.4±0.1 g/cm3
- LogP:3.96
- 折射率1.629
- 蒸汽压0.0±0.7 mmHg at 25°C
- 储存条件Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
- 产品应用该化合物是抗风疹呼吸器中的一个重要制剂.VORICONAZOLE是针对侵入性真菌感染的一种三联甲联苯抗菌剂,它表现出高度的个体之间和个人内部的药用动能变异性.VORICONAZOLOLE是一种用于治疗侵入性菌感染的抗风素药物.
MSDS等安全信息
上下游产品
(2R,3S/2S,3R)-3-(6-氯-5-氟嘧啶-4-基)-2-(2,4-二氟苯基)-1-(1H-1,2,4-三唑-1-基)-2-丁醇盐酸盐 3-(6-Chloro-5-Fluoropyrimidin-4-yl)-2-(2,4-Difluorophenyl)-1-(1H-1,2,4-Triazol-1-yl)-2-Butanol 188416-35-5合成工艺路线路线简述
📜(2R,3S/2S,3R)-3-(6-氯-5-氟嘧啶-4-基)-2-(2,4-二氟苯基)-1-(1H-1,2,4-三唑-1-基)-2-丁醇盐酸盐置于palladium 10% On Activated Carbon 氢气,Sodium Acetate体系中,用 水,乙酸乙酯 用作溶剂,25.0~30.0 °C,490.34 Kpa 条件下,反应生成伏立康唑杂质8
参考文献: Process For The Preparation Of Voriconazole[fr] Procédé De Préparation De Voriconazole
标题: Process For The Preparation Of Voriconazole[fr] Procédé De Préparation De Voriconazole
摘要:本发明提供了一种在单个反应容器中制备顺式伏立康唑的方法.本发明还提供了一种使用顺式伏立康唑制备伏立康唑的方法以及与之相关的制备过程.
海关参考信息
- 2902600000-乙苯
2902700000-异丙基苯
2905122000-异丙醇
2906210000-苄醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR 3rd, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016 Feb 20;387(10020):760-9. doi: 10.1016/S0140-6736(15)01159-9. Epub 2015 Dec 10. 212(1):157-165. doi: 10.2214/AJR.18.19991. Epub 2018 Nov 7. 36(5):786-95. doi: 10.1055/s-0035-1562903. Epub 2015 Sep 23. 78(11):2630-2636. doi: 10.1093/jac/dkad293. 181(18):V12180870. Danish. 15(5):493-502. doi: 10.1080/14787210.2017.1305886. Epub 2017 Mar 24. 88(12):5166-5182. doi: 10.1111/bcp.15495. Epub 2022 Aug 25. 28(3):e671. doi: 10.1097/RHU.0000000000001850. 50(7):489-494. doi: 10.1080/23744235.2017.1418531. Epub 2017 Dec 20. 51(3):247-265. doi: 10.1080/03602532.2019.1632888. Epub 2019 Aug 16. 27(2):151-160. doi: 10.1016/j.jiac.2020.11.014. Epub 2020 Dec 26. 61(4):106750. doi: 10.1016/j.ijantimicag.2023.106750. Epub 2023 Feb 8. 66(9):e0017722. doi: 10.1128/aac.00177-22. Epub 2022 Aug 15.
14: Zhong X, Tong X, Ju Y, Du X, Li Y. Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision? Curr Drug Metab. 2018;19(14):1152-1158. doi: 10.2174/1389200219666171227200547.
15: Kadam RS, Van Den Anker JN. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy. Clin Pharmacokinet. 2016 Sep;55(9):1031-43. doi: 10.1007/s40262-016-0379-2.
📝 需求与反馈
尽可能描述清楚需求与问题信息
